How Lab-Grown Organoids Are Revolutionizing Drug Discovery and FDA Trials

Organoid technology has transformed drug discovery by offering a faster, more accurate way to test treatments. These tiny lab-grown structures mimic human organs, bridging the gap between simple cell tests and expensive animal studies. Their development over the past 15 years has opened new doors in medical research and regulatory approvals. The field took its first major step in 2009 when the Hans Clevers laboratory created the first intestinal organoid. By 2013, scientists had successfully grown retinal, brain, liver, kidney, and pancreatic versions. Two years later, prostate, lung, and mammary gland organoids followed, expanding the technology’s reach.

In 2020 and 2021, researchers pushed boundaries further by culturing snake venom gland and chondrosarcoma organoids. These advances showed the method’s versatility across different biological systems. Meanwhile, the U.S. FDA launched its Tissue Chip Drug Screening Program in 2010, aiming to develop organ-mimicking chips for more reliable drug tests. A key milestone arrived in 2022 when the FDA approved a clinical trial for SAR445088, a drug developed using only organoid-on-a-chip data. This marked the first time a treatment skipped traditional animal testing under the FDA Modernization Act 2.0, which now permits alternative preclinical methods. Despite progress, challenges remain, particularly in standardising culture techniques and fully replicating complex organ environments. Organoids have also proven vital in studying regenerative processes, infectious diseases, and organ development. Their ability to model human biology in the lab speeds up research and reduces reliance on animal experiments.

The shift toward organoid-based testing is reshaping drug development and regulatory pathways. With the FDA now accepting alternative preclinical methods, more treatments could reach trials faster and at lower costs. However, refining the technology to consistently mirror human organs remains a priority for future breakthroughs.